secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009363
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q1 2023 net loss $7.8M; HOPE-3 DMD trial interim analysis on track for Q4 2023
--------------------------------------------------------------------------------

- Net loss $7.8M ($0.31 per share) flat YoY; revenue $3.0M from Nippon Shinyaku deal vs zero prior year.
- Cash, equivalents and marketables $45.2M; runway into Q4 2024, excludes milestone payments.
- HOPE-3 Phase 3 for CAP-1002 in DMD: 13 active sites, targeting full enrollment by H2 2023, interim analysis Q4 2023.
- 24-month HOPE-2 open-label extension data planned for presentation in Q2 2023.
- Received $12M upfront from Japan partner Nippon Shinyaku; potential milestones up to ~$89M plus revenue share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/0001558370-23-009363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/capr-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer